scholarly journals Probiotic Bifidobacterium breve in Improving Cognitive Functions of Older Adults with Suspected Mild Cognitive Impairment: A Randomized, Double-Blind, Placebo-Controlled Trial

2020 ◽  
pp. 1-9 ◽  
Author(s):  
Jinzhong Xiao ◽  
Noriko Katsumata ◽  
Francois Bernier ◽  
Kazuya Ohno ◽  
Yuki Yamauchi ◽  
...  
Keyword(s):  
Older Adults ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Cognitive Functions ◽  
Controlled Trial ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Bifidobacterium Breve

scholarly journals Effects of 12 Weeks Cosmos caudatus Supplement among Older Adults with Mild Cognitive Impairment: A Randomized, Double-Blind and Placebo-Controlled Trial

Nutrients ◽  
2021 ◽  
Vol 13 (2) ◽  
pp. 434
Author(s):  
Yee Xing You ◽  
Suzana Shahar ◽  
Nor Fadilah Rajab ◽  
Hasnah Haron ◽  
Hanis Mastura Yahya ◽  
...  
Keyword(s):  
Older Adults ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Controlled Trial ◽  
Mood Disturbance ◽  
Double Blind ◽  
Blood Biochemical ◽  
Cosmos Caudatus ◽  
Total Mood Disturbance ◽  
Biochemical Profiles

Cosmos caudatus (CC) contains high flavonoids and might be beneficial in neuroprotection. It has the potential to prevent neurodegenerative diseases. Therefore, we aimed to investigate the effects of 12 weeks of Cosmos caudatus supplement on cognitive function, mood status, blood biochemical profiles and biomarkers among older adults with mild cognitive impairment (MCI) through a double-blind, placebo-controlled trial. The subjects were randomized into CC supplement (n = 24) and placebo group (n = 24). Each of them consumed one capsule of CC supplement (250 mg of CC/capsule) or placebo (500 mg maltodextrin/capsule) twice daily for 12 weeks. Cognitive function and mood status were assessed at baseline, 6th week, and 12th week using validated neuropsychological tests. Blood biochemical profiles and biomarkers were measured at baseline and 12th week. Two-way mixed analysis of variance (ANOVA) analysis showed significant improvements in mini mental state examination (MMSE) (partial η2 = 0.150, p = 0.049), tension (partial η2 = 0.191, p = 0.018), total mood disturbance (partial η2 = 0.171, p = 0.028) and malondialdehyde (MDA) (partial η2 = 0.097, p = 0.047) following CC supplementation. In conclusion, 12 weeks CC supplementation potentially improved global cognition, tension, total mood disturbance, and oxidative stress among older adults with MCI. Larger sample size and longer period of intervention with incorporation of metabolomic approach should be conducted to further investigate the underlying mechanism of CC supplementation in neuroprotection.

A Randomized, Double-blind, Placebo Controlled-trial of Triflusal in Mild Cognitive Impairment

2008 ◽  
Vol 22 (1) ◽  
pp. 21-29 ◽  
Author(s):  
Teresa Gómez-Isla ◽  
Rafael Blesa ◽  
Merce Boada ◽  
Jordi Clarimón ◽  
Teodoro Del Ser ◽  
...  
Keyword(s):  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Controlled Trial ◽  
Double Blind ◽  
Double Blind Placebo

scholarly journals Methylphenidate for Mild Cognitive Impairment: An Exploratory 3-Day, Randomized, Double-Blind, Placebo-Controlled Trial

2021 ◽  
Vol 8 ◽  
Author(s):  
Yan Press ◽  
Boris Punchik ◽  
Ella Kagan ◽  
Alexander Berzak ◽  
Tamar Freud ◽  
...  
Keyword(s):  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Adverse Events ◽  
Verbal Memory ◽  
Cognitive Assessment ◽  
Controlled Trial ◽  
Immediate Release ◽  
Cognitive Outcome ◽  
Double Blind ◽  
Double Blind Placebo

Background: To evaluate the efficacy, safety and tolerability of methylphenidate (MPH) for cognitive function in older patients with mild cognitive impairment (MCI).Methods: Male and female subjects aged 65 years and older with a clinical diagnosis MCI were included in an exploratory randomized, double-blind, placebo-controlled trial. Eligible subjects were assigned to either treatment with immediate-release MPH or placebo. The active compound was administered in an increasing-dose stepwise fashion, namely 10 mg MPH on day 1, 20 mg on day 2, and 30 mg on day 3. Subjects remained under observation for 4 h following drug administration and were monitored for changes in blood pressure and for adverse events. Cognitive outcome measures included the Montreal Cognitive Assessment (MoCA) and the Neurotrax Mindstreams computerized cognitive assessment battery.Results: Of 17 subjects enrolled, 15 subjects completed the study, 7 in the active MPH group and 8 in the placebo group. The average age of the participants was 76.1 ± 6.6 years and 10 (66.7%) were men. Following the final dose a significant benefit on memory (predominantly non-verbal memory) was found in the MPH group. While 12 adverse events were reported, they were all rated as mild to moderate.Conclusions: Our finding of modest beneficial effects of MPH on memory tests in older subjects with MCI in this exploratory study is of interest and should be investigated in further studies.

Sign in / Sign up

Export Citation Format

Share Document